Skip to main content

Crohns Disease

Immunology
3
Pipeline Programs
8
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 8 programs with unclassified modality

Immunology is a $15.0B market in mature growth, driven by blockbuster JAK inhibitors and biologics across multiple therapeutic domains.

$15.0B marketMature↑ Growing30 products15 companies

Key Trends

  • JAK inhibitors and corticosteroid combinations dominate spending (39% combined)
  • Multiple patent cliffs emerging 2026-2028, creating generic competition risk
  • Robust pipeline with 4,996 trials signals continued innovation and market expansion

Career Verdict

Strong career opportunity for those targeting Medical Affairs, Commercial, or R&D roles, with solid hiring momentum and premium salaries in specialized functions.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1MOUNJAROGrowing
$2.4B
#2SYMBICORTStable
$2.0B
AstraZeneca·LOE_APPROACHING
#3JAKAFIDeclining
$1.9B
Incyte·LOE_APPROACHING2.6yr
#4RESTASISStable
$1.5B
AbbVie·PEAK8.0yr
#5RINVOQGrowing
$976M
AbbVie·PEAK11.8yr

Drug Class Breakdown

Janus Kinase Inhibitors
$3.0B(20%)

dominant class with patent cliff risk

Corticosteroid Hormone Receptor Agonists
$2.8B(19%)

established, mature market segment

G-Protein-linked Receptor Interactions
$2.4B(16%)

driven by single blockbuster

Calcineurin Inhibitors
$1.6B(11%)

established immunosuppression class

Tumor Necrosis Factor Receptor Blocking Activity
$1.2B(8%)

legacy biologic class with competition

Career Outlook

Growing

Immunology offers a maturing but actively growing market with strong corporate investment, deep pipelines, and premium compensation across commercial and clinical functions. The therapeutic area is characterized by complex mechanism-of-action portfolios, frequent label expansion opportunities, and multi-indication blockbusters that require sophisticated Medical Affairs and Commercial expertise. Patent cliff risk on JAK inhibitors creates both disruption and opportunity for those skilled in competitive positioning and pipeline strategy.

Breaking In

Enter through Medical Affairs, Clinical Operations, or Commercial Training programs at large companies (J&J, AbbVie, Bristol Myers Squibb); a foundation in immunology mechanisms is valuable but trainable.

For Experienced Professionals

Leverage patent cliff risk to position yourself in competitive differentiation, pipeline strategy, or M&A integration roles, where demand for immunology expertise is highest.

In-Demand Skills

Medical Affairs and MSL expertise in immunosuppression and inflammatory diseasesJAK inhibitor mechanism expertise and competitive positioningClinical trial design and phase transition managementCommercial acumen for premium-priced biologics and small moleculesRegulatory strategy for label expansions and lifecycle management

Best For

Medical Science LiaisonBrand ManagerSenior Medical Affairs ManagerClinical Development ManagerCommercial Strategy Lead

Hiring Landscape

$212K-$387K

Immunology hiring totals 340 open positions with strong demand across Medical Affairs (110 roles, $257K avg), Commercial (83 roles, $270K avg), and R&D (31 roles, $387K avg). Johnson & Johnson, Bristol Myers Squibb, and AbbVie are the top recruiters, reflecting their portfolio depth and market dominance. Compensation is competitive, particularly in R&D and Clinical Operations.

340
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

45Growing
31Growing
29Stable

By Department

Medical Affairs(32%)
$257K
Commercial(24%)
$270K
Research & Development(9%)
$387K
Clinical Operations(4%)
$345K
Manufacturing(2%)
$212K

Strong hiring demand with premium compensation in Medical Affairs and Commercial roles; R&D positions command highest salaries but are less abundant.

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
1 program
1
AfimkibartPhase 21 trial
Active Trials
NCT05910528Active Not Recruiting21Est. Dec 2030
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
GSK2330811Phase 2
Medtronic
MedtronicNJ - Phillipsburg
1 program
1
glatiramer acetatePhase 21 trial
Active Trials
NCT00731172Unknown50Est. Jul 2011
UCB Pharma
UCB PharmaBelgium - Brussels
2 programs
CertolizumabN/AMonoclonal Antibody1 trial
Exam under anesthesiaN/A1 trial
Active Trials
NCT01582568Terminated1Est. Mar 2014
NCT01145365Completed21Est. Jun 2015
Teva
TevaIsrael - Petach Tikva
2 programs
Delayed Release 6 mercaptopurinePHASE_11 trial
glatiramer acetatePHASE_2
Active Trials
NCT00774982Completed12Est. Feb 2009
Celularity
CelularityFLORHAM PARK, NJ
1 program
PDA001PHASE_11 trial
Active Trials
NCT01769755Completed14Est. Nov 2014
Tr1X
Tr1XCA - San Diego
1 program
TRX103PHASE_1_21 trial
Active Trials
NCT06721962Recruiting39Est. Jan 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
GenentechAfimkibart
Medtronicglatiramer acetate
Tr1XTRX103
CelularityPDA001
TevaDelayed Release 6 mercaptopurine
UCB PharmaCertolizumab
UCB PharmaExam under anesthesia

Clinical Trials (7)

Total enrollment: 158 patients across 7 trials

Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

Start: Jul 2023Est. completion: Dec 203021 patients
Phase 2Active Not Recruiting
NCT00731172Medtronicglatiramer acetate

A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease

Start: Sep 2008Est. completion: Jul 201150 patients
Phase 2Unknown

Treatment of Moderate to Severe Refractory Crohn's Disease

Start: May 2025Est. completion: Jan 202739 patients
Phase 1/2Recruiting

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Start: Mar 2013Est. completion: Nov 201414 patients
Phase 1Completed
NCT00774982TevaDelayed Release 6 mercaptopurine

Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients

Start: Dec 2008Est. completion: Feb 200912 patients
Phase 1Completed

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

Start: Jun 2011Est. completion: Mar 20141 patients
N/ATerminated
NCT01145365UCB PharmaExam under anesthesia

Study to Look at Benefit of Surgical Drainage Before Beginning Medical Therapy for Crohns Perianal Fistulas

Start: Dec 2010Est. completion: Jun 201521 patients
N/ACompleted

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 158 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.